WallStSmart

Astrana Health Inc (ASTH)vsUniversal Health Services Inc (UHS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Universal Health Services Inc generates 446% more annual revenue ($17.36B vs $3.18B). ASTH leads profitability with a 71.0% profit margin vs 8.6%. UHS trades at a lower P/E of 8.1x. UHS earns a higher WallStSmart Score of 76/100 (B+).

ASTH

Hold

46

out of 100

Grade: D+

Growth: 7.3Profit: 6.0Value: 3.0Quality: 5.0

UHS

Strong Buy

76

out of 100

Grade: B+

Growth: 7.3Profit: 7.0Value: 10.0Quality: 7.5
Piotroski: 6/9Altman Z: 2.97
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ASTHSignificantly Overvalued (-508.0%)

Margin of Safety

-508.0%

Fair Value

$3.13

Current Price

$24.48

$21.35 premium

UndervaluedFair: $3.13Overvalued
UHSUndervalued (+78.6%)

Margin of Safety

+78.6%

Fair Value

$1081.08

Current Price

$186.72

$894.36 discount

UndervaluedFair: $1081.08Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ASTH3 strengths · Avg: 9.3/10
Profit MarginProfitability
71.0%10/10

Keeps 71 of every $100 in revenue as profit

Revenue GrowthGrowth
42.9%10/10

Revenue surging 42.9% year-over-year

Price/BookValuation
1.5x8/10

Reasonable price relative to book value

UHS4 strengths · Avg: 8.8/10
P/E RatioValuation
8.1x10/10

Attractively priced relative to earnings

Return on EquityProfitability
21.3%9/10

Every $100 of equity generates 21 in profit

Price/BookValuation
1.6x8/10

Reasonable price relative to book value

EPS GrowthGrowth
42.7%8/10

Earnings expanding 42.7% YoY

Areas to Watch

ASTH4 concerns · Avg: 2.8/10
Market CapQuality
$1.36B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
4.5%3/10

ROE of 4.5% — below average capital efficiency

Operating MarginProfitability
1.9%3/10

Operating margin of 1.9%

P/E RatioValuation
53.2x2/10

Premium valuation, high expectations priced in

UHS0 concerns · Avg: 0/10

No major concerns identified

Comparative Analysis Report

WallStSmart Research

Bull Case : ASTH

The strongest argument for ASTH centers on Profit Margin, Revenue Growth, Price/Book. Profitability is solid with margins at 71.0% and operating margin at 1.9%. Revenue growth of 42.9% demonstrates continued momentum.

Bull Case : UHS

The strongest argument for UHS centers on P/E Ratio, Return on Equity, Price/Book. PEG of 1.29 suggests the stock is reasonably priced for its growth.

Bear Case : ASTH

The primary concerns for ASTH are Market Cap, Return on Equity, Operating Margin. A P/E of 53.2x leaves little room for execution misses.

Bear Case : UHS

No major red flags identified for UHS, but monitor valuation.

Key Dynamics to Monitor

ASTH profiles as a growth stock while UHS is a value play — different risk/reward profiles.

UHS carries more volatility with a beta of 1.26 — expect wider price swings.

ASTH is growing revenue faster at 42.9% — sustainability is the question.

UHS generates stronger free cash flow (293M), providing more financial flexibility.

Bottom Line

UHS scores higher overall (76/100 vs 46/100). Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Astrana Health Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Astrana Health, Inc., Inc., a physician-centric technology-powered healthcare management company, provides medical care services in the United States. The company is headquartered in Alhambra, California.

Universal Health Services Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

UnitedHealth Group Incorporated is an American for-profit multinational managed healthcare and insurance company based in Minnetonka, Minnesota. It offers health care products and insurance services.

Visit Website →

Want to dig deeper into these stocks?